Customized data and analyses to address pharmaceutical and biotech pipeline or portfolio challenges
Evaluate Custom Solutions
Testimonials
“ Evaluate Custom Solutions paid careful attention to our report needs, and the after-care service was excellent, so our level of satisfaction was extremely high. It was one of the best services that I have experienced so far. ”
Motomu Himori, Specialist, Chugai Pharmaceutical Co., Ltd.
“ I really could not do my job without Evaluate data. You guys make me look good all the time. ”
Business Development & Licensing, Large Pharmaceutical
Over the last year, 13 of the world’s largest pharmaceutical and biotech companies have engaged Evaluate Custom Solutions in addressing their biggest global challenges. These clients have engaged us to provide insight to help inform a range of their key objectives including: Market Analysis & Competitor Intelligence, Corporate Strategy & Franchise Planning, Market Expansion & Forecasting, Mergers & Acquisition, New Product Development, Market Access and Pricing & Commercialization.
Below are some examples of the work we have undertaken for the likes of Abbvie, Amgen, AstraZeneca, Bayer, Daiichi Sankyo, Gilead, GSK, Johnson & Johnson/Janssen, Merck KGaA, Novartis, Pfizer, Roche/Chugai and Sanofi.
Corporate Strategy Teams
An external industry perspective to complement your views on the market, competition, and your company's strategic direction.
Find out how a major global pharma gained an external perspective on market trends to support a key Executive Team strategy session.
R&D Strategy & Portfolio Planning
Objective, data-driven insights to validate if you are making the right choices for your product portfolio.
Find out how a Japanese pharma company benchmarked the R&D productivity of peer companies for insight into potential patterns and drivers.
Business Development & Licensing
Expedite your search and screen efforts and access robust, data-driven analysis to support opportunity assessment.
Find out how a mid-sized pharma BD&L team outsourced their search and screen efforts for a shortlist of assets with potential for licensing.
Commercial Operations, Pricing & Forecasting
Customized epidemiology research, forecast modelling, and pricing analysis to inform your product strategy and tactical planning.
Find out how a pharma commercial and finance group established a standard forecasting methodology across an entire business.
Digital & Data Science Teams
Feed industry-leading Evaluate commercial intelligence directly into your internal tools, systems and workflows via data feeds and APIs.
Find out how a major US pharma created a live M&A target screening tool by integrating Evaluate data into a data visualization dashboard.
Our services are designed for teams defining product and portfolio strategy and setting direction for key brands and franchises. We provide insight into Market Analysis & Competitor Intelligence, Corporate Strategy & Franchise Planning, Market Expansion & Forecasting, Mergers & Acquisition, New Product Development, Market Access and Pricing & Commercialization.
Leveraging a foundation of extensive Evaluate data augmented with further secondary research, modelling, and analysis, our solutions are data-driven and insight-focused. We also conduct targeted primary research with Key Opinion Leaders, Healthcare Professionals and Payers to validate our assumptions and test our hypotheses.
Below we have provided an overview of our services and how they apply to the life stages of companies / products. If there is something that is not listed here please contact us so we can work with you to get you the insights you need.
Please click on the “+” to read our case studies.
Discovery & Preclinical
Early Clinical Development (P1-P2a)
Late Clinical Development (P2b-P3)
Commercialisation
Market Analysis & Competitive Intelligence
High impact, forward-looking insight into market trends and the drivers fuelling the growth of the industry, providing outside-in perspectives on market evolution and your company’s positioning in the landscape.
Please click the links below for our case studies:
- Insights to provide “outside-in” context to a post-M&A Executive team strategy session
- Analysis to support long-range therapy area strategy review for a major US pharma
- Peer company R&D productivity benchmarking for a major Japanese pharma
- Regular reporting of key competitor developments for a major European pharma
Industry trend & growth driver analysis
Productivity & return on investment benchmarking
Indication landscape & evolution analysis
Competitor strategy profiling
Competitive landscape evolution and outlook
Epidemiology Modelling & Systematic Literature Review
Rigorous research and analysis to construct fully customised and focused fit-for-purpose epidemiology models, designed to underpin market sizing, opportunity assessment, product targeting, and product value measurement.
Please click the links below for our case studies:
Burden of illness & incidence/prevalence studies
Global/regional/country-specific patient segmentation modelling
Standard of care & treatment paradigm definition
Clinical outcomes & treatment pattern studies
Market sizing & unmet need identification
Oncology patient dynamic flow modelling
Rare disease epidemiology
Opportunity Identification & Quantification
Robust comparative assessments leveraging unique Evaluate metrics and incorporating scientific, clinical, and commercial drivers, providing insights to guide informed portfolio strategy and prioritisation decision making.
Please click the links below for our case studies:
- Supporting licensing target identification and prioritisation for a mid-sized Canadian pharma
- Insights into global technology research trends to support strategic review for a major Japanese pharma
- Analysis of evolving unmet clinical needs and competitor activity for a major Japanese pharma
- Asset due diligence and sales forecast development to support investment thesis validation for a major global life sciences investor
Market profiling & segment analysis
Indication sizing, scoring & prioritisation
Competitive intensity analysis
Market opportunity analysis & forecasting
Opportunity identification, fit & prioritisation assessment
BD&L target search, screen & assessment
Partner identification & profiling
Deal benchmarking analysis
Product Strategy & Differentiation
Deep analysis of product differentiators and value in the context of an ever evolving and dynamic market, providing objective perspectives to influence product targeting and strategy in support of development planning, fund-raising, and deal-making.
Please click the links below for our case studies:
- Supporting early pipeline program target indication selection for a mid-sized Japanese pharma
- Analysis of lead asset optimal development pathway and commercial potential for a US biotech
- Pan-tumour portfolio asset valuation for early phase US biotech
- Epidemiology & patient-based in-depth global forecast models for oncology and rare-disease areas
- Product pricing analysis across multiple countries for multiple price points
Niche identification & addressable population sizing
Product positioning & differentiation assessment
Target product profile (TPP) definition & testing
Price benchmarking & sensitivity analysis
Scenario-based sales & volume forecast modelling
Product targeting & development strategy assessment
Data Feeds & APIs
Programmatic access to Evaluate data
Get in touch
Get in touch
Resources
An introduction to Custom Solutions
Our unmatched combination of industry renowned forecasts, proprietary methodologies and ubiquitous products along with our highly qualified, multi-disciplined experts; uniquely positions us as the only choice when you need cost-effective, deeply analytical, data-driven insight. Please download to find out more.
Establishing Rare Disease Prevalence
Largely driven by the payer environment, the focus of drug development has shifted in the last 10 years to rare diseases. Due to the lack of solid epidemiology data available, over 7,000 rare diseases (many being sub-sets of larger diseases), have not been quantified, posing a problem when using prevalent population estimates to create forecasts. This document discusses the challenges in determining accurate patient population estimates for rare diseases and the best practice methodologies to arrive at appropriate prevalent and incident population figures.
Asset valuations in Healthcare
Healthcare is a heavily specialist arena and it is not always easy to understand what a quality valuation should be based on and include. Accurate consideration of true drivers of the market is both an art and a science. This document breaks the valuation down in to its constituent income and expenditure parts and discusses the level of detail that is expected.
Oncology Market Forecasting
Most analysts can find forecasting in oncology daunting as it is a highly specialised and technical area, mixed with plenty of seemingly impenetrable terms. This document addresses these nuances and breaks them down so they can be digested more easily to help readers fully optimize their forecasting.